

Redx Pharma plc

(“Redx” or the “Company”)

Notification of Preliminary Results and Webcast

Alderley Park, 14 January 2021 Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, will be releasing its preliminary results for the full year ended 30 September 2020 on 27 January 2021.

A live webcast for analysts will be held at 12.00pm on 27 January 2021. To join the webcast, please register in advance by sending an e-mail to redxpharma@fticonsulting.com.

A recording of the webcast will be made available on Redx Pharma’s website following the results meeting.

For further information, please contact:

Redx Pharma Plc

Iain Ross, Chairman

Lisa Anson, Chief Executive

T: +44 1625 469 918

SPARK Advisory Partners (Nominated Adviser)

Matt Davis/Adam Dawes

T: +44 203 368 3550

WG Partners LLP (Broker)

Claes Spång/Chris Lee/David Wilson

T: +44 20 3705 9330

FTI Consulting

Simon Conway/Ciara Martin

T: +44 20 3727 1000

About Redx Pharma Plc

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx’s lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company’s selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.

The Company’s core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).